The role of the somatostatin analogues in large cell neuroendocrine carcinomas treatment

#3702

Introduction: Large cell neuroendocrine carcinoma (LCNEC) is still a poorly studied disease with low somatostatin receptors expression, so we have scant data on the effectiveness of the somatostatin analogues (SSA) in this disease.

Aim(s): Evaluation of the prevalence of SSTR in the LCNEC group, effect of SSTR on the course of LCNEC, effectiveness of adding SSA to the main chemotherapeutic (ChT) treatment in LCNEC.

Materials and methods: 42 LCNEC patients (pts) with median age of 51 (22-64) of various origins were included in the study: Pancreas (24%, n=10), stomach/esophagus (24%), lungs (19%) and others (33%). 79% (n=33) had stage IV disease. Median ki-67 was 71% (45-90%). 55% were female. Progression-free (PFS) and overall survival (OS) were accessed by Kaplan-Meier survival analysis, IBM SPSS Statistics v.26.

Conference:

Presenting Author: Evdokimova E

Authors: Evdokimova E, Artamonova E, Delektorskaya V, Yemelyanova G, Markovich A,

Keywords: NEC, SSTR, somatostatin analogues, large cell carcinoma, SSA, LCNEC, somatostatin receptor,